Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

aluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN-701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company expects to enroll up to 30 patients between the ages of 13 and 65 years old with late-onset Pompe disease for a treatment period of 24 weeks.  The primary objective of the study is to establish the maximum tolerated dose of every other week administration of BMN-701 and to treat an expanded cohort of patients at the maximum tolerated dose.

Preclinical Programs

  • BMN-111 for Achondroplasia: BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP) for achondroplasia, a small cyclic peptide that is a positive regulator of bone growth.  Achondroplasia is the most common form of dwarfism.  There are approximately between 18,000 and 24,000 patients in the U.S. and Europe, 25 percent of which is the estimated addressable market.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three months and year ended December 31, 2010 and December 31, 2009 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release for the three months and year ended December 31, 2010 and December 31, 2009, non-GAAP income is calculated in accordance with GAAP, but excludes non-cash stock compensation expense and certain nonrecurring material items. The financial guidance for the year ending December 31, 2011 is based on Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring materia
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
    2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
    3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
    4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
    5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
    6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
    7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
    8. BioMarin Announces Third Quarter 2010 Financial Results
    9. BioMarin to Host a Research and Development Day on October 19th
    10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    11. BioMarin to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in Boston.  The public is welcome to participate ... Array BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: ... 10, 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
    (Date:9/2/2015)... , Sept. 2, 2015 ... revenue base with highly profitable specialty products ... Near-term growth potential with 11 product applications pending ... IV certifications  , Provides medium and longer ... development, including eight controlled substances , Adds ...
    (Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ... Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... provide a detailed overview of the key areas of pharmaceutical ... Hong Kong , Macau and ... - All important aspects of gaining and maintaining a ...
    Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
    ... today announced the,publication of the results from a ... cruciate ligament (ACL) reconstruction,surgery. OMS103HP is an investigational ... and is designed to improve postoperative,knee function and ... return to work. The article titled "Novel Drug ...
    ... PHILADELPHIA, Aug. 25 Scientists have,discovered gene mutations ... the childhood cancer neuroblastoma. In addition, the researchers found,that ... forms of,non-inherited neuroblastoma, the more common form of the ... first genetic tests to families,affected by the inherited form ...
    Cached Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4
    (Date:9/3/2015)... ... September 03, 2015 , ... The new ... Report of Provo, Utah. The Clinicians Report is a leading information source to ... located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for ...
    (Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
    (Date:9/3/2015)... ... September 03, 2015 , ... The partnership ... customer and technical support services to promote LodonalTM in Nigeria. The distribution will ... the efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, ...
    (Date:9/2/2015)... ... ... One can hardly argue against the fact that more and more people are using ... are being used as GPS, to make purchases, and yes, even to find a ... can now join the prestigious social ranks of e-dating. , Recently, Mr. Josh ...
    (Date:9/2/2015)... Poulsbo, WA (PRWEB) , ... September 02, 2015 , ... ... store, open September 2015. “It was a simple decision, really,” says Chris. “We have ... shop here. They know the brands that work best for them—so we’ve given them ...
    Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2
    ... are worried, as the floodplains of the Yamuna river are ... and even hotels for the 2010 Commonwealth Games. ... danger for the city's water security, they warn. ... weekend at Rajghat in New Delhi. It is being organized ...
    ... Taser to control agitated suspects in police custody is ... In some circles, however, the idea that using a ... controversy. ,Now, the final results of a ... of California, San Diego (UCSD) Medical Center showed no ...
    ... on black silk. The imagery is powerful and the prospect ... have turned to cocaine in a big way, throwing ... for instance, once hailed as a brilliant advocate, is ... naked and unconscious last Friday in a hotel room by ...
    ... positive effect on someones physical health? This question is ... of the latest Medical Journal of Australia. ... and spirituality in health, its relevance to Australian practitioners ... practice, and the current gaps where more research is ...
    ... hydropower projects being clean, a new scientific study has ... for at least 19 percent of India's global ... study, Indian dams are larger methane emitters and total ... around 33.5 million tonnes (MT) per annum, including emissions ...
    ... in the mouth like a popular breath-freshener could someday ... The innovative drug-delivery system was developed by Johns ... two-semester course, the seven-student team fabricated a thin film ... the child to swallow the vaccine. The dissolved medication ...
    Cached Medicine News:Health News:Green Campaigners Concerned About Yamuna's Shrinking Floodplains 2Health News:Healthy Humans Not Harmed By Taser 2Health News:Australia Agonising Over the Problem of Cocaine Use by Lawyers 2Health News:Australia Agonising Over the Problem of Cocaine Use by Lawyers 3Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 3
    The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
    Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
    The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
    The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
    Medicine Products: